var data={"title":"Treatment of oropharyngeal and esophageal candidiasis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment of oropharyngeal and esophageal candidiasis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/contributors\" class=\"contributor contributor_credentials\">Carol A Kauffman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/contributors\" class=\"contributor contributor_credentials\">Kieren A Marr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 24, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Candida</em> species can be associated with infections involving mucosal membranes, including the oropharynx and esophagus. The majority of these infections are related to <em>Candida albicans</em>. Oropharyngeal infection is often asymptomatic unless it is associated with lower tract disease, which is usually characterized by dysphagia or odynophagia.</p><p>The treatment of oropharyngeal candidiasis or esophageal candidiasis will be discussed below. The clinical manifestations of oropharyngeal and esophageal candidiasis are discussed elsewhere. (See <a href=\"topic.htm?path=clinical-manifestations-of-oropharyngeal-and-esophageal-candidiasis\" class=\"medical medical_review\">&quot;Clinical manifestations of oropharyngeal and esophageal candidiasis&quot;</a> and <a href=\"topic.htm?path=evaluation-of-the-hiv-infected-patient-with-odynophagia-and-dysphagia\" class=\"medical medical_review\">&quot;Evaluation of the HIV-infected patient with odynophagia and dysphagia&quot;</a> and <a href=\"topic.htm?path=overview-of-candida-infections\" class=\"medical medical_review\">&quot;Overview of Candida infections&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">OROPHARYNGEAL CANDIDIASIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The preferred therapy for the treatment of oropharyngeal candidiasis differs by patient population. The general duration of treatment is 7 to 14 days [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1\" class=\"abstract_t\">1</a>]. For any given drug, not all individuals with a clinical response will achieve a mycological response; however rates of relapse within one month tend to be lower when a mycological cure is obtained.</p><p>Considerations for treatment choice include drug effectiveness, severity of infection, ease of administration, anticipated adherence, gastric acidity (which may affect absorption), drug-drug interactions, and cost.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">HIV-seronegative patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of oropharyngeal candidiasis in patients without AIDS is usually accomplished with local therapy for 7 to 14 days [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1-3\" class=\"abstract_t\">1-3</a>]. For topical agents, successful therapy depends on adequate contact time between the agent and the oral mucosa [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/4\" class=\"abstract_t\">4</a>]. Options include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=clotrimazole-drug-information\" class=\"drug drug_general\">Clotrimazole</a> troches (one 10-mg troche dissolved slowly five times daily) are effective, but can be difficult to adhere to due to frequent dosing [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/5\" class=\"abstract_t\">5</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=miconazole-drug-information\" class=\"drug drug_general\">Miconazole</a> mucoadhesive buccal tablets (50 mg once daily applied to the mucosal surface over the canine fossa) are as effective as <a href=\"topic.htm?path=clotrimazole-drug-information\" class=\"drug drug_general\">clotrimazole</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/6\" class=\"abstract_t\">6</a>], but may be more expensive.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=nystatin-drug-information\" class=\"drug drug_general\">Nystatin</a> swish and swallow (400,000 to 600,000 units four times daily) has been used for many years, but is not always palatable to patients [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/5\" class=\"abstract_t\">5</a>]. It also contains sucrose, which can cause dental caries when used over prolonged time periods [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/4\" class=\"abstract_t\">4</a>]. </p><p/><p>If the patient does not respond to these local measures, the preferred therapy is oral <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (200 mg loading dose, then 100 to 200 mg daily) [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1,2,7,8\" class=\"abstract_t\">1,2,7,8</a>]. Clinical symptoms and signs resolve in more than 90 percent of patients taking fluconazole [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/9\" class=\"abstract_t\">9</a>].</p><p>In a study of 279 cancer patients who were receiving cytotoxic drugs, patients were randomly assigned to either <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> or <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/10\" class=\"abstract_t\">10</a>]. The clinical cure rate was significantly higher for fluconazole (74 versus 62 percent). The mycological cure rate was also significantly better in those patients treated with fluconazole (80 versus 68 percent). Studies of other alternative therapies have been mainly conducted in HIV-infected patients. (See <a href=\"#H4\" class=\"local\">'HIV-seropositive patients'</a> below.)</p><p>Therapy for denture stomatitis requires treatment of the device as well as the oral cavity to avoid relapse [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/9\" class=\"abstract_t\">9</a>]. The dentures must be removed before going to bed, brushed vigorously, and then soaked in a solution of <a href=\"topic.htm?path=chlorhexidine-gluconate-drug-information\" class=\"drug drug_general\">chlorhexidine</a> gluconate or a dilute solution of bleach (10 drops in a denture cup filled with water). Other products (sold as Polident or Efferdent) can also be used but may not be as effective [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1,3,11\" class=\"abstract_t\">1,3,11</a>].</p><p>Recurrence is common if the underlying risk factors are still present, (eg, ongoing steroid use or chemotherapy). In these patients, oral troches are a reasonable first approach; for more persistent infections, prophylactic therapy with 100 mg <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> daily is a good option. Some patients with radiation-induced xerostomia have recurrent episodes of candidiasis after the radiation therapy is finished. It is probably better to treat when symptoms appear than to give continuous fluconazole suppression, which increases the risk of developing azole resistance [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1,2,8\" class=\"abstract_t\">1,2,8</a>]. Drug-resistant <em>Candida glabrata </em>infection in patients with head and neck cancer has been described in two case series, and in both, higher dosages of fluconazole were required for eradication of disease [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/12,13\" class=\"abstract_t\">12,13</a>]. (See <a href=\"#H25\" class=\"local\">'Drug resistance'</a> below.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">HIV-seropositive patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Oropharyngeal candidiasis is the most common opportunistic infection in persons infected with HIV [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/14,15\" class=\"abstract_t\">14,15</a>]. The development of oropharyngeal candidiasis in an HIV-infected patient is usually associated with significant immunosuppression (CD4 counts &lt;200 <span class=\"nowrap\">cells/microL)</span> [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/14\" class=\"abstract_t\">14</a>]. Prior colonization and a history of oral candidiasis are other significant risk factors [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/16\" class=\"abstract_t\">16</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">General approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The approach to treatment of oropharyngeal candidiasis can include topical agents or azole therapy. (See <a href=\"#H6\" class=\"local\">'Topical therapy'</a> below and <a href=\"#H7\" class=\"local\">'Azole therapy'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend the use of topical agents for patients with their first presentation of mild thrush. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with moderate to severe oropharyngeal candidiasis or for those with recurrent disease, we recommend <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> due to its effectiveness, palatability, ease of administration, and cost, as suggested by major guideline committees [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1\" class=\"abstract_t\">1</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We also recommend <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> rather than topical therapy in patients who are at risk of developing esophageal candidiasis (CD4 count &lt;100 <span class=\"nowrap\">cells/microL)</span>.</p><p/><p>For patients who fail <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> therapy, azoles such as <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, and <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> can be used. Echinocandins and <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> are also suggested in the Infectious Diseases Society of America guidelines as treatment for refractory thrush [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1\" class=\"abstract_t\">1</a>], but these are rarely indicated. </p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Topical therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients presenting with an initial episode of mild thrush, topical therapy can be administered for 7 to 14 days. We prefer <a href=\"topic.htm?path=clotrimazole-drug-information\" class=\"drug drug_general\">clotrimazole</a> troches (one 10 mg troche five times daily), but <a href=\"topic.htm?path=miconazole-drug-information\" class=\"drug drug_general\">miconazole</a> mucoadhesive buccal tablets (50 mg once daily applied to the mucosal surface over the canine fossa) can also be used. A randomized study of 578 HIV-infected individuals found that daily application of the 50 mg mucoadhesive buccal tablet of miconazole was as effective as clotrimazole troches used five times daily [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/6\" class=\"abstract_t\">6</a>]. </p><p><a href=\"topic.htm?path=nystatin-drug-information\" class=\"drug drug_general\">Nystatin</a> suspension (400,000 to 600,000 units four times daily) is another option. However, it may be less effective than <a href=\"topic.htm?path=clotrimazole-drug-information\" class=\"drug drug_general\">clotrimazole</a> or <a href=\"topic.htm?path=miconazole-drug-information\" class=\"drug drug_general\">miconazole</a>. Studies that have compared clotrimazole troches or nystatin to <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> found that clotrimazole troches had comparable effectiveness to oral fluconazole, whereas nystatin was clearly inferior [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/17,18\" class=\"abstract_t\">17,18</a>]. <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">Amphotericin B deoxycholate</a> oral suspension is available in some countries for use in refractory thrush; however, it is not available in the United States.</p><p>Other topical therapies, such as antifungal creams, are suitable for the treatment of angular cheilitis, which can be seen as a manifestation of <em>Candida</em> infection in immunosuppressed hosts. Angular cheilitis manifests as bilateral, bright red erythematous fissures at the angles of the mouth [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/19\" class=\"abstract_t\">19</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Azole therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Azole therapies include <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> and <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>. <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">Posaconazole</a> has been shown to be effective for oropharyngeal candidiasis [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/20\" class=\"abstract_t\">20</a>]. There are few data on the use of <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, although its efficacy for esophageal candidiasis suggests it would be efficacious for oropharyngeal candidiasis.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h4\">Fluconazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In randomized, controlled trials, oral <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> was demonstrated to be as effective and convenient, and better tolerated than topical therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/18,21\" class=\"abstract_t\">18,21</a>]. In addition, it is associated with less risk of relapse and a longer disease-free interval [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/18,21,22\" class=\"abstract_t\">18,21,22</a>]. The dose recommended is 200 mg loading dose, followed by 100 to 200 mg daily for 7 to 14 days [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a study of 167 HIV-infected patients, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> was demonstrated to be more efficacious than topical <a href=\"topic.htm?path=nystatin-drug-information\" class=\"drug drug_general\">nystatin</a> with clinical cure rates of 87 and 52 percent, respectively [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/18\" class=\"abstract_t\">18</a>]. Mycological cure rates were also superior with fluconazole.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a large study of 334 HIV-infected patients with oral candidiasis, patients were randomly assigned to either 14 days of <a href=\"topic.htm?path=clotrimazole-drug-information\" class=\"drug drug_general\">clotrimazole</a> troches (10 mg five times daily) or <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (100 mg daily). Both therapies were found to be clinically effective (94 percent compared to 98 percent) [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/17\" class=\"abstract_t\">17</a>].</p><p/><p>However, mycological cure during primary therapy is higher with <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> than with either <a href=\"topic.htm?path=clotrimazole-drug-information\" class=\"drug drug_general\">clotrimazole</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/17\" class=\"abstract_t\">17</a>] or <a href=\"topic.htm?path=nystatin-drug-information\" class=\"drug drug_general\">nystatin</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/18\" class=\"abstract_t\">18</a>] and clinical relapse is more common with nystatin than with azole therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/17,18\" class=\"abstract_t\">17,18</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h4\">Itraconazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">Itraconazole</a> solution is as effective as <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> 200 mg daily for the treatment of oropharyngeal candidiasis and is more effective than topical therapy with <a href=\"topic.htm?path=clotrimazole-drug-information\" class=\"drug drug_general\">clotrimazole</a> in mycological cure rates [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/23-25\" class=\"abstract_t\">23-25</a>]. Itraconazole capsules should <strong>not </strong>be used; although they are more palatable than the solution, they are less effective due to their variable absorption.</p><p>For most patients, we generally prefer <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> because <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> has been associated with nausea in more than 10 percent of patients [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1\" class=\"abstract_t\">1</a>]. In addition, itraconazole is a more potent inhibitor of cytochrome p450 enzymes than fluconazole, which increases the risk of drug interactions (see <a href=\"topic.htm?path=pharmacology-of-azoles\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;</a>). However, itraconazole solution (200 mg once daily for up to 28 days) is a suitable option for patients with fluconazole refractory disease (eg, those who clinically fail fluconazole therapy) [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1,26\" class=\"abstract_t\">1,26</a>]. </p><p>Clinical trial data supporting the use of <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> for oropharyngeal candidiasis include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a double-blind trial of 244 HIV-infected patients, <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> oral solution was as clinically effective as <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (90 percent in both groups) [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/23\" class=\"abstract_t\">23</a>]. The incidence of early relapse (within 30 days) occurred in approximately one-third of both treatment groups; drug tolerability was comparable.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another randomized, controlled trial of 147 patients with mycologically proven oropharyngeal candidiasis, <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> oral solution (10 <span class=\"nowrap\">mg/mL,</span> 200 mg daily for 7 to 14 days) was demonstrated to be as effective as <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/24\" class=\"abstract_t\">24</a>].</p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h4\">Posaconazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">Posaconazole</a> is an extended-spectrum triazole with potent in vitro activity against most <em>Candida</em> species, including some fluconazole-resistant strains. (See <a href=\"topic.htm?path=pharmacology-of-azoles#H2\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Overview of clinical uses'</a>.)</p><p>The role of <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> for treating uncomplicated oropharyngeal candidiasis is unclear since <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> is as effective and much less expensive [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/5,26\" class=\"abstract_t\">5,26</a>]. However, posaconazole suspension may be an effective alternative for patients with refractory disease. For such patients, posaconazole should be administered 400 mg twice daily for three days and then once daily for up to 28 days. </p><p>Clinical trial data supporting the use of <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> suspension include: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a multicenter, randomized trial of 350 HIV-infected patients with oropharyngeal candidiasis, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> suspension and <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> suspension (each administered as 200 mg on day one followed by 100 mg once daily for 13 days) were both highly effective in producing favorable outcomes (97 percent in both groups) [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/20\" class=\"abstract_t\">20</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In an open-label trial in 149 HIV-infected patients treated with <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> suspension (400 mg once or twice daily) for oropharyngeal candidiasis refractory to <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> or <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, clinical cure or improvement occurred in 74 percent of patients [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/27\" class=\"abstract_t\">27</a>].</p><p/><p>Studies demonstrating the efficacy of <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> for thrush were performed with the oral suspension. An extended release tablet has been subsequently made available. When compared with the oral suspension, the tablet has improved absorption and can achieve higher serum concentrations. Thus, most physicians have switched to the tablet formulation for treatment of invasive fungal infections and prophylaxis in immunosuppressed hosts. However, it is unclear how the use of the tablet formulation will impact the efficacy of posaconazole for oropharyngeal candidiasis because it is not known if serum concentrations determine the response of thrush to therapy or if there is a benefit from the local effects of the suspension.</p><p class=\"headingAnchor\" id=\"H739993444\"><span class=\"h4\">Voriconazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">Voriconazole</a> 200 mg twice daily for up to 28 days can be used to treat oropharyngeal infection caused by <em>Candida</em> species that are resistant to <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1,26\" class=\"abstract_t\">1,26</a>]. However, data are limited [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/28\" class=\"abstract_t\">28</a>], and there are no trials comparing fluconazole with voriconazole for treatment of fluconazole susceptible strains.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">ESOPHAGEAL CANDIDIASIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most cases of esophageal candidiasis are secondary to <em>C. albicans</em>. The risk of disease is increased in HIV-infected patients with advanced immunosuppression (CD4 count &lt;100 <span class=\"nowrap\">cells/microL)</span> and in those with oropharyngeal thrush [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/29,30\" class=\"abstract_t\">29,30</a>]. However, the absence of oropharyngeal thrush does not rule out the possibility of <em>Candida</em> esophagitis. The introduction of potent antiretroviral therapy has been associated with a marked diminution in esophageal candidiasis and in treatment-refractory cases [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/26\" class=\"abstract_t\">26</a>].</p><p>Esophageal candidiasis also occurs in HIV-seronegative patients who are taking inhaled corticosteroids and in cancer patients [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/31,32\" class=\"abstract_t\">31,32</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">General approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Candida</em> esophagitis requires systemic antifungal therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/26\" class=\"abstract_t\">26</a>]; it should never be managed with local agents [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/2\" class=\"abstract_t\">2</a>].</p><p>An empiric course of antifungal therapy is appropriate in the immunosuppressed patient with symptoms of odynophagia or dysphagia; endoscopy can be performed if symptoms do not improve after approximately 72 hours [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/21\" class=\"abstract_t\">21</a>]. The threshold for doing endoscopy is lower in patients without evidence of oral thrush, since other etiologies may be causing the patient's symptoms. The general duration of treatment is 14 to 21 days [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1\" class=\"abstract_t\">1</a>]. Intravenous therapy may be required initially in patients with severe disease who cannot take oral therapy.</p><p>The treatment of esophageal candidiasis can include azoles, echinocandins, or amphotericin B, as discussed below. We recommend <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> for the treatment of esophageal candidiasis due to its excellent efficacy, ease of administration, and low cost. For patients with documented esophageal candidiasis that is refractory to fluconazole after one week of treatment, we recommend <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> or <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> in outpatients. <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">Itraconazole</a> oral suspension is also effective, but causes more nausea. In patients in whom intravenous therapy is necessary, we suggest use of an echinocandin, rather than amphotericin B, as discussed below.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Azole therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Potential agents in the azole class include <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> solution, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, and <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Fluconazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In three randomized trials, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> was superior to <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a>, <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a>, and <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> for the treatment of esophageal candidiasis [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/33-35\" class=\"abstract_t\">33-35</a>]. In a number of trials and smaller studies, the effectiveness of fluconazole therapy has ranged from 80 to 90 percent [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/2,36-41\" class=\"abstract_t\">2,36-41</a>]. Its ease of administration, lack of toxicity, and cost also favor its use [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/5,42\" class=\"abstract_t\">5,42</a>]. The dose is 400 mg as a loading dose and then 200 to 400 mg daily for 14 to 21 days given orally or intravenously, as tolerated [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">Itraconazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Three randomized, controlled trials demonstrated that <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> oral solution (200 mg daily) was as effective as <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/35-37,43\" class=\"abstract_t\">35-37,43</a>]. However, itraconazole solution can cause nausea and has more drug-drug interactions than fluconazole. Itraconazole capsules should not be used due to variability of absorption, resulting in compromised efficacy. (See <a href=\"topic.htm?path=pharmacology-of-azoles\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h3\">Voriconazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">Voriconazole</a> appears to be as effective as <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> for the treatment of esophageal candidiasis and has been used to treat patients who were unresponsive to fluconazole [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/38,44\" class=\"abstract_t\">38,44</a>]. </p><p>A double-blind, multicenter trial was performed to evaluate the comparative efficacy of oral <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (loading dose of 400 mg followed by 200 mg once daily) or oral <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (200 mg twice daily) for the treatment of proven esophageal candidiasis in 391 immunocompromised patients, most of whom had underlying AIDS [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/38\" class=\"abstract_t\">38</a>]. Voriconazole and fluconazole resulted in similar rates of microbiologic cure, as assessed by repeat esophagoscopy (98 versus 95 percent, respectively). The most common side effect associated with voriconazole was mild, transient visual disturbances (23 percent). However, voriconazole has more drug-drug interactions than fluconazole and should be used as a second-line agent.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h3\">Posaconazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">Posaconazole</a> oral suspension, 400 mg twice daily, led to a clinical response in 32 of 43 patients (74 percent) with endoscopically documented esophageal candidiasis, which had been refractory to primary therapy with <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> or <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/27\" class=\"abstract_t\">27</a>]. The role of the extended release posaconazole tablet in the treatment of esophageal candidiasis has not been studied. </p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Echinocandins</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The echinocandins (<a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a>, <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a>, and <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a>) are also effective for the treatment of <em>Candida</em> esophagitis [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/39-41,45-48\" class=\"abstract_t\">39-41,45-48</a>]. All of the echinocandins must be given intravenously, and therefore, are used mostly in the treatment of hospitalized patients and those patients who have esophageal candidiasis refractory to azole therapy; they are also much more expensive than <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/5\" class=\"abstract_t\">5</a>]. Most studies have shown higher relapse rates with echinocandins than with azoles except at higher dosages of the echinocandins [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/39,40,48\" class=\"abstract_t\">39,40,48</a>]. For this reason, the recommended doses of some echinocandins for the treatment of esophageal candidiasis are higher than those used for candidemia.</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h3\">Caspofungin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In a double-blind, randomized trial, 177 patients with esophageal candidiasis were randomly assigned to receive either <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> (50 mg intravenously) or <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (200 mg intravenously) once daily for 7 to 21 days [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/39\" class=\"abstract_t\">39</a>]. The primary endpoint was the combined response of symptom resolution and significant endoscopic improvement five to seven days after discontinuation of therapy. Favorable responses were seen in 81 percent of patients in the caspofungin arm and 85 percent of patients on the fluconazole arm. Symptoms recurred in 18 (28 percent) of 64 patients given caspofungin and in 12 (17 percent) of 72 patients given fluconazole.</p><p><a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">Caspofungin</a> also appears to be effective in the treatment of esophageal candidiasis resistant to <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> and is a less toxic alternative to intravenous amphotericin B [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/49\" class=\"abstract_t\">49</a>]. A retrospective analysis of its efficacy was performed in patients with esophagitis who had resistant isolates or a refractory clinical infection (no improvement after one week of fluconazole therapy) [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/49\" class=\"abstract_t\">49</a>]. Caspofungin led to a favorable clinical response in the majority of patients with in vitro resistant isolates (11 of 14) and in those with clinically refractory disease (7 of 11).</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h3\">Micafungin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with esophageal candidiasis, the dose of <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a> is 150 mg intravenously per day. Micafungin has been evaluated in the treatment of esophageal candidiasis in HIV-infected patients with the following results:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A dose-ranging study of <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a> (12.5, 50, 75, and 100 mg daily) in 120 HIV-infected patients with esophageal candidiasis demonstrated that those who received 75 or 100 mg per day had more favorable clinical and endoscopic outcomes [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/47\" class=\"abstract_t\">47</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another dose-ranging study of 245 adults with AIDS and culture proven esophageal candidiasis, the endoscopic cure rate was dose dependent at 69 percent, 77 percent and 90 percent with 50, 100, and 150 mg of <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a>, respectively [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/40\" class=\"abstract_t\">40</a>]. Cure rates at the two higher doses of micafungin were comparable to its comparator, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, at 200 mg daily.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a large, controlled non-inferiority trial of 523 predominantly HIV-infected patients with esophageal candidiasis, <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a> (150 mg) was compared with <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (200 mg daily) for efficacy and safety [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/48\" class=\"abstract_t\">48</a>]. Therapy was given for a mean of 14 days. Endoscopic cure was documented in 88 percent of patients in both arms; relapse rates were 15 percent for micafungin and 11 percent for fluconazole. Based on this study, 150 mg of micafungin is the recommended dose for the treatment of esophageal candidiasis.</p><p/><p class=\"headingAnchor\" id=\"H21\"><span class=\"h3\">Anidulafungin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">Anidulafungin</a> is typically administered to individuals who failed or had an adverse reaction to <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1\" class=\"abstract_t\">1</a>]. Anidulafungin should be given at a dose of 200 mg daily for the treatment of esophageal candidiasis because lower doses have higher relapse rates. </p><p>A randomized, double-blind trial in 601 patients with esophageal candidiasis compared <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a> (100 mg on day one, followed by 50 mg per day) to <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (200 mg on day one, followed by 100 mg per day) [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/41\" class=\"abstract_t\">41</a>]. Initial clinical and endoscopic improvement was similar in both arms (97 percent with anidulafungin versus 99 percent with fluconazole). However, endoscopic relapse was more common in the anidulafungin arm than the fluconazole arm (53 versus 19 percent). Thus, higher doses of anidulafungin (ie, 200 mg daily) are recommended [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Amphotericin B</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">Amphotericin B deoxycholate</a> (0.3 to 0.7 <span class=\"nowrap\">mg/kg</span> daily) is also an effective agent for <em>Candida</em> esophagitis [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/50\" class=\"abstract_t\">50</a>]. However, its use is limited because it is given intravenously and is associated with more toxicity than other antifungal drugs (eg, the echinocandins).</p><p>The clinical indications for amphotericin B therapy include, drug resistant <em>Candida</em> infections and esophageal candidiasis during pregnancy (see <a href=\"#H25\" class=\"local\">'Drug resistance'</a> below and <a href=\"#H23\" class=\"local\">'Treatment during pregnancy'</a> below). Isolates of <em>C. glabrata</em> and <em>C. krusei</em> may require higher doses of amphotericin B (0.7 <span class=\"nowrap\">mg/kg)</span> [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h1\">TREATMENT DURING PREGNANCY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Azoles are teratogenic and should not be used during the first trimester for the treatment of mucosal candidiasis [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/51\" class=\"abstract_t\">51</a>]. There are no data regarding the use of echinocandins in pregnancy. Amphotericin B is recommended [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/21\" class=\"abstract_t\">21</a>].</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h1\">ADVERSE EFFECTS OF THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Short courses of topical therapy rarely result in adverse effects.</p><p>Azole therapy can be associated with gastrointestinal upset; prolonged administration can cause hepatotoxicity; periodic monitoring of aminotransferases is prudent with chronic administration. <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">Voriconazole</a> is the only azole associated with visual disturbances and has a higher risk of rash, including photosensitivity, than other azoles.</p><p>Echinocandins are very well tolerated, but require intravenous administration. Drug interactions are uncommon because, unlike the azoles, these drugs are not metabolized via the cytochrome p450 pathway [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/52\" class=\"abstract_t\">52</a>].</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h1\">DRUG RESISTANCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The emergence of drug resistance has been mostly reported for azoles, particularly <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> and <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/8,53-55\" class=\"abstract_t\">8,53-55</a>]. Risk factors in HIV-infected patients include advanced immunosuppression and chronic exposure to azoles [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/55\" class=\"abstract_t\">55</a>]. A large, randomized trial found that the rate of development of clinical fluconazole resistance was the same for individuals receiving long-term suppressive therapy as for those receiving episodic therapy; however, the <em>Candida</em> isolates recovered from the patients receiving continuous therapy showed reduced susceptibility to fluconazole in vitro [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/56\" class=\"abstract_t\">56</a>].</p><p>Refractory mucosal candidiasis is sometimes due to non-<em>albicans</em> species, such as <em>C. glabrata</em> or <em>C. krusei</em> [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/57\" class=\"abstract_t\">57</a>]. Fluconazole-resistant candidiasis can be treated with <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, an echinocandin, or intravenous <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1,21,26\" class=\"abstract_t\">1,21,26</a>].</p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the era before effective antiretroviral therapy (ART) was available, the risk of developing resistant candidiasis was related to a CD4 count less than 50 <span class=\"nowrap\">cells/microL</span> and to prolonged azole therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/58\" class=\"abstract_t\">58</a>]. Use of effective ART has been associated with both declining rates of persistent carriage of <em>C. albicans</em> and reduced frequency of symptomatic episodes of oropharyngeal candidiasis [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/59,60\" class=\"abstract_t\">59,60</a>]. In patients with AIDS, ART plays an important role in preventing recurrent disease [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Long-term suppressive therapy with <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> is effective in the prevention of oropharyngeal candidiasis in patients with AIDS [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/56\" class=\"abstract_t\">56</a>]. However, most HIV specialists do not recommend primary or secondary prophylaxis due to the effectiveness of therapy for acute disease, the low mortality associated with mucosal candidiasis, the potential for resistance and drug interactions, and the associated cost [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/21,26,61\" class=\"abstract_t\">21,26,61</a>]. This topic is also discussed elsewhere. (See <a href=\"topic.htm?path=overview-of-prevention-of-opportunistic-infections-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Overview of prevention of opportunistic infections in HIV-infected patients&quot;</a>.)</p><p>Some have suggested that prophylaxis be considered in the individual with frequent or severe mucosal infections and in developing countries where the rates of invasive fungal disease, such as cryptococcosis, are much higher [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/61,62\" class=\"abstract_t\">61,62</a>]. Patients with a history of one or more episodes of esophageal candidiasis, who have not attained immune reconstitution on antiretroviral therapy, are good candidates for secondary prophylaxis; <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> at 100 to 200 mg three times weekly is appropriate [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/21,56,63\" class=\"abstract_t\">21,56,63</a>]. However, prolonged use of systemically absorbed azoles in patients with CD4 counts less than 100 <span class=\"nowrap\">cells/microL</span> increases the risk for developing resistance; these implications should be considered in any long-term treatment plan [<a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/21\" class=\"abstract_t\">21</a>].</p><p class=\"headingAnchor\" id=\"H3031831627\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-candidiasis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Candidiasis&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-opportunistic-infections-in-hiv-infected-adults-and-adolescents\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Opportunistic infections in HIV-infected adults and adolescents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here is the patient education article that is relevant to this topic. We encourage you to print or e-mail this topic to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topic (see <a href=\"topic.htm?path=thrush-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Thrush (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H27\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"headingAnchor\" id=\"H28\"><span class=\"h2\">Oropharyngeal candidiasis</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oropharyngeal candidiasis is a local infection of older adults who wear dentures, patients treated with antibiotics, steroids, chemotherapy, or radiation therapy to the head and neck, and those with cellular immune deficiency states, such as AIDS. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend topical therapy for the treatment of oropharyngeal candidiasis in patients without AIDS (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H3\" class=\"local\">'HIV-seronegative patients'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend topical therapy for the initial episode of oropharyngeal candidiasis in HIV-infected patients with mild disease (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). For patients with recurrent infection, moderate to severe disease, or in those with advanced immunosuppression (CD4 &lt;100 <span class=\"nowrap\">cells/microL)</span> we recommend <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (200 mg loading dose, followed by 100 to 200 mg daily for 7 to 14 days after clinical improvement) (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). (See <a href=\"#H4\" class=\"local\">'HIV-seropositive patients'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with fluconazole-refractory disease (eg, those who clinically fail <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> therapy), we administer <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> solution, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> suspension, or <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> for up to 28 days. (See <a href=\"#H2\" class=\"local\">'Oropharyngeal candidiasis'</a> above.) </p><p/><p class=\"headingAnchor\" id=\"H29\"><span class=\"h2\">Esophageal candidiasis</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Esophageal candidiasis is most commonly seen in HIV-infected patients with advanced immunosuppression (CD4 &lt;200 <span class=\"nowrap\">cells/microL)</span>. The presence of oropharyngeal candidiasis increases the risk of this disease; however, its absence does not eliminate the diagnosis. (See <a href=\"#H11\" class=\"local\">'Esophageal candidiasis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Empiric antifungal therapy can be initiated with careful follow-up. Endoscopy should be undertaken if the patient has no improvement of symptoms in 72 hours. (See <a href=\"#H11\" class=\"local\">'Esophageal candidiasis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend systemic agents for the treatment of documented or suspected esophageal candidiasis (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). (See <a href=\"#H11\" class=\"local\">'Esophageal candidiasis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (400 mg loading dose followed by 200 to 400 mg daily for 14 to 21 days) for the treatment of esophageal candidiasis due to its ease of administration, lack of toxicity, and lower cost (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). (See <a href=\"#H11\" class=\"local\">'Esophageal candidiasis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with documented esophageal candidiasis that is refractory to <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> after one week of treatment, we recommend <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> or <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> for outpatients (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). In patients in whom intravenous therapy is necessary, we suggest use of an echinocandin, rather than amphotericin B&nbsp;(<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H11\" class=\"local\">'Esophageal candidiasis'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/1\" class=\"nounderline abstract_t\">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/2\" class=\"nounderline abstract_t\">Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998; 26:259.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/3\" class=\"nounderline abstract_t\">Shay K, Truhlar MR, Renner RP. Oropharyngeal candidosis in the older patient. J Am Geriatr Soc 1997; 45:863.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/4\" class=\"nounderline abstract_t\">Patton LL, Bonito AJ, Shugars DA. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92:170.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/5\" class=\"nounderline abstract_t\">Klotz SA. Oropharyngeal candidiasis: a new treatment option. Clin Infect Dis 2006; 42:1187.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/6\" class=\"nounderline abstract_t\">Vazquez JA, Patton LL, Epstein JB, et al. Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad&reg; efficacy and safety (SMiLES). HIV Clin Trials 2010; 11:186.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/7\" class=\"nounderline abstract_t\">Koletar SL, Russell JA, Fass RJ, Plouffe JF. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1990; 34:2267.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/8\" class=\"nounderline abstract_t\">Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97:339.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/9\" class=\"nounderline abstract_t\">Finlay PM, Richardson MD, Robertson AG. A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours. Br J Oral Maxillofac Surg 1996; 34:23.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/10\" class=\"nounderline abstract_t\">Oude Lashof AM, De Bock R, Herbrecht R, et al. An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. Eur J Cancer 2004; 40:1314.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/11\" class=\"nounderline abstract_t\">Iacopino AM, Wathen WF. Oral candidal infection and denture stomatitis: a comprehensive review. J Am Dent Assoc 1992; 123:46.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/12\" class=\"nounderline abstract_t\">Redding SW, Dahiya MC, Kirkpatrick WR, et al. Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 97:47.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/13\" class=\"nounderline abstract_t\">Redding SW, Kirkpatrick WR, Coco BJ, et al. Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J Clin Microbiol 2002; 40:1879.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/14\" class=\"nounderline abstract_t\">Klein RS, Harris CA, Small CB, et al. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 1984; 311:354.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/15\" class=\"nounderline abstract_t\">Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996; 124:633.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/16\" class=\"nounderline abstract_t\">MacPhail LA, Hilton JF, Dodd CL, Greenspan D. Prophylaxis with nystatin pastilles for HIV-associated oral candidiasis. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:470.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/17\" class=\"nounderline abstract_t\">Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group. J Acquir Immune Defic Syndr 1993; 6:1311.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/18\" class=\"nounderline abstract_t\">Pons V, Greenspan D, Lozada-Nur F, et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997; 24:1204.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/19\" class=\"nounderline abstract_t\">Sharon V, Fazel N. Oral candidiasis and angular cheilitis. Dermatol Ther 2010; 23:230.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/20\" class=\"nounderline abstract_t\">Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006; 42:1179.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/21\" class=\"nounderline abstract_t\">Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/22\" class=\"nounderline abstract_t\">Goa KL, Barradell LB. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50:658.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/23\" class=\"nounderline abstract_t\">Phillips P, De Beule K, Frechette G, et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis 1998; 26:1368.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/24\" class=\"nounderline abstract_t\">Graybill JR, Vazquez J, Darouiche RO, et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998; 104:33.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/25\" class=\"nounderline abstract_t\">Murray PA, Koletar SL, Mallegol I, et al. Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clin Ther 1997; 19:471.</a></li><li class=\"breakAll\">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on December 08, 2015).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/27\" class=\"nounderline abstract_t\">Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44:607.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/28\" class=\"nounderline abstract_t\">Hegener P, Troke PF, F&auml;tkenheuer G, et al. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 1998; 12:2227.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/29\" class=\"nounderline abstract_t\">Wilcox CM, Straub RF, Clark WS. Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration. Am J Gastroenterol 1995; 90:1938.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/30\" class=\"nounderline abstract_t\">Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients. Arch Intern Med 1991; 151:1567.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/31\" class=\"nounderline abstract_t\">Kanda N, Yasuba H, Takahashi T, et al. Prevalence of esophageal candidiasis among patients treated with inhaled fluticasone propionate. Am J Gastroenterol 2003; 98:2146.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/32\" class=\"nounderline abstract_t\">Samonis G, Skordilis P, Maraki S, et al. Oropharyngeal candidiasis as a marker for esophageal candidiasis in patients with cancer. Clin Infect Dis 1998; 27:283.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/33\" class=\"nounderline abstract_t\">Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann Intern Med 1992; 117:655.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/34\" class=\"nounderline abstract_t\">Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study. Endoscopy 1995; 27:377.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/35\" class=\"nounderline abstract_t\">Barbaro G, Barbarini G, Calderon W, et al. Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida Esophagitis. Gastroenterology 1996; 111:1169.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/36\" class=\"nounderline abstract_t\">Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Scand J Infect Dis 1995; 27:613.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/37\" class=\"nounderline abstract_t\">Wilcox CM, Darouiche RO, Laine L, et al. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997; 176:227.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/38\" class=\"nounderline abstract_t\">Ally R, Sch&uuml;rmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33:1447.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/39\" class=\"nounderline abstract_t\">Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113:294.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/40\" class=\"nounderline abstract_t\">de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39:842.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/41\" class=\"nounderline abstract_t\">Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39:770.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/42\" class=\"nounderline abstract_t\">Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43:1060.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/43\" class=\"nounderline abstract_t\">Vazquez JA. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials 2000; 1:47.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/44\" class=\"nounderline abstract_t\">Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/45\" class=\"nounderline abstract_t\">Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33:1529.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/46\" class=\"nounderline abstract_t\">Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46:451.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/47\" class=\"nounderline abstract_t\">Pettengell K, Mynhardt J, Kluyts T, et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004; 20:475.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/48\" class=\"nounderline abstract_t\">de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21:899.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/49\" class=\"nounderline abstract_t\">Kartsonis N, DiNubile MJ, Bartizal K, et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002; 31:183.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/50\" class=\"nounderline abstract_t\">Lake DE, Kunzweiler J, Beer M, et al. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Chemotherapy 1996; 42:308.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/51\" class=\"nounderline abstract_t\">Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996; 22:336.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/52\" class=\"nounderline abstract_t\">Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006; 42:1171.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/53\" class=\"nounderline abstract_t\">Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 2000; 30:749.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/54\" class=\"nounderline abstract_t\">Maenza JR, Merz WG, Romagnoli MJ, et al. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997; 24:28.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/55\" class=\"nounderline abstract_t\">Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:219.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/56\" class=\"nounderline abstract_t\">Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis 2005; 41:1473.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/57\" class=\"nounderline abstract_t\">Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1997; 25:843.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/58\" class=\"nounderline abstract_t\">Fichtenbaum CJ, Powderly WG. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis 1998; 26:556.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/59\" class=\"nounderline abstract_t\">Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27:1291.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/60\" class=\"nounderline abstract_t\">Cauda R, Tacconelli E, Tumbarello M, et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr 1999; 21:20.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/61\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Rapid assessment of injuries among survivors of the terrorist attack on the World Trade Center--New York City, September 2001. MMWR Morb Mortal Wkly Rep 2002; 51:1.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/62\" class=\"nounderline abstract_t\">Bozzette SA. Fluconazole prophylaxis in HIV disease, revisited. Clin Infect Dis 2005; 41:1481.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-oropharyngeal-and-esophageal-candidiasis/abstract/63\" class=\"nounderline abstract_t\">Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332:700.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2432 Version 20.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H27\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">OROPHARYNGEAL CANDIDIASIS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">HIV-seronegative patients</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">HIV-seropositive patients</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">- General approach</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">- Topical therapy</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">- Azole therapy</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Fluconazole</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Itraconazole</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Posaconazole</a></li><li><a href=\"#H739993444\" id=\"outline-link-H739993444\">Voriconazole</a></li></ul></li></ul></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">ESOPHAGEAL CANDIDIASIS</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">General approach</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Azole therapy</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">- Fluconazole</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">- Itraconazole</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">- Voriconazole</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">- Posaconazole</a></li></ul></li><li><a href=\"#H18\" id=\"outline-link-H18\">Echinocandins</a><ul><li><a href=\"#H19\" id=\"outline-link-H19\">- Caspofungin</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">- Micafungin</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">- Anidulafungin</a></li></ul></li><li><a href=\"#H22\" id=\"outline-link-H22\">Amphotericin B</a></li></ul></li><li><a href=\"#H23\" id=\"outline-link-H23\">TREATMENT DURING PREGNANCY</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">ADVERSE EFFECTS OF THERAPY</a></li><li><a href=\"#H25\" id=\"outline-link-H25\">DRUG RESISTANCE</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">PREVENTION</a></li><li><a href=\"#H3031831627\" id=\"outline-link-H3031831627\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H25504915\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H27\" id=\"outline-link-H27\">SUMMARY AND RECOMMENDATIONS</a><ul><li><a href=\"#H28\" id=\"outline-link-H28\">Oropharyngeal candidiasis</a></li><li><a href=\"#H29\" id=\"outline-link-H29\">Esophageal candidiasis</a></li></ul></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-oropharyngeal-and-esophageal-candidiasis\" class=\"medical medical_review\">Clinical manifestations of oropharyngeal and esophageal candidiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-the-hiv-infected-patient-with-odynophagia-and-dysphagia\" class=\"medical medical_review\">Evaluation of the HIV-infected patient with odynophagia and dysphagia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-candida-infections\" class=\"medical medical_review\">Overview of Candida infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-prevention-of-opportunistic-infections-in-hiv-infected-patients\" class=\"medical medical_review\">Overview of prevention of opportunistic infections in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=thrush-the-basics\" class=\"medical medical_basics\">Patient education: Thrush (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-azoles\" class=\"medical medical_review\">Pharmacology of azoles</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-candidiasis\" class=\"medical medical_society_guidelines\">Society guideline links: Candidiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-opportunistic-infections-in-hiv-infected-adults-and-adolescents\" class=\"medical medical_society_guidelines\">Society guideline links: Opportunistic infections in HIV-infected adults and adolescents</a></li></ul></div></div>","javascript":null}